NeuroOne® to Ring Nasdaq Stock Market Closing Bell on November 22

Ceremony to commemorate recent FDA clearance milestone for Company's Evo® sEEG Electrode technology

EDEN PRAIRIE, Minn., Nov. 22, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that it will ring the Nasdaq closing bell today Tuesday, November 22, 2022, to commemorate its recent corporate milestone achievement for the Evo® thin film electrode platform.

The NeuroOne closing bell ceremony will be broadcast live starting at 3:50 p.m. Eastern Time from Nasdaq MarketSite in New York City's Times Square. The live broadcast may be viewed on Livestream and Facebook. Following an introduction by Nasdaq, NeuroOne CEO Dave Rosa will deliver brief remarks and then ring the bell at 4:00 p.m. alongside other members of the NeuroOne team.

Dave Rosa commented, "Last month we received FDA 510(k) clearance to market our Evo sEEG Electrode technology for temporary (less than 30 days) use with equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain. This was our Company's most exciting achievement to date, rounding out the full functionality of our Evo sEEG System* and advancing our manufacturing ramp and commercialization efforts for this advanced line of diagnostic electrodes. We are excited to celebrate this victory at Nasdaq's iconic bell ringing ceremony."

*Caution: Federal law restricts this device to sale by or on the order of a physician.

NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. For more information, visit www.n1mtc.com.

This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this presentation may be a forward–looking statement that reflects NeuroOne's current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words or phrases "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "target," "seek," "contemplate," "continue, "focused on," "committed to" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding our manufacturing ramp and commercialization activities. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that the partnership with Zimmer Biomet may not facilitate the commercialization or market acceptance of our technology; risks that our sEEG electrodes may not be ready for commercialization in a timely manner or at all, whether due to supply chain disruptions, labor shortages, the impact of COVID-19 or otherwise; risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials; risks related to uncertainties associated with the Company's capital requirements to achieve its business objectives and ability to raise additional funds; the risk that the COVID-19 pandemic will continue to adversely impact our business; the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology; uncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements or decisions of regulatory authorities; that we may not have accurately estimated the size and growth potential of the markets for our technology; risks relate to clinical trial patient enrollment and the results of clinical trials; that we may be unable to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described under the heading "Risk Factors" in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.

SOURCE NeuroOne Medical Technologies Corporation

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED